Daijiworld Media Network – Mumbai
Mumbai, Jun 3: Dental tech startup Toothsi, known for offering clear aligners as a convenient and affordable alternative to braces, is now under fire from a growing number of dissatisfied customers who allege mismanagement, misleading practices, and poor after-sales service.
Social media platform X and consumer complaint forums have seen a surge in posts from disgruntled users. One such user, advocate Geet Dhir, publicly urged the company to send his next batch of aligners, having completed the previous set with no follow-up. "Send new aligner at the earliest to me. I insist as well request," he posted, highlighting service delays.
Another user, Shivendra Soni, minced no words in calling Toothsi a scam. "Toothsi app and Toothsi is a scam… Mere paise pure barbaad huye," he said, accusing staff of making false promises.
A deeper investigation by The Ken revealed multiple such complaints. Priya, a marketing executive from Mumbai, shared her ordeal after paying Rs 50,000 for the service. "They rejected impressions I hadn’t even sent," she said. The company then demanded Rs 11,000 more for a 3D scan, which she believes was a tactic to extract additional payment.
Fahima N, another user who filed a complaint via Voxya, recounted a troubling experience. Despite being promised a fully remote treatment, she was asked to travel long distances for procedures and was told to undergo a tooth extraction local dentist later called unsafe. Her aligners arrived before any extraction was approved, raising questions about the product's customisation.
Even attempts to cancel the service reportedly hit a wall, with customers being told loans had already been processed.
Toothsi’s parent company, MakeO—which also operates skincare brand Skinnsi—had raised major funding in January 2025 at a valuation of Rs 2,231 cr. However, industry reports now suggest the company is struggling to attract new investment and may have to settle for a valuation nearly half of its earlier peak.
As user complaints mount, the company faces increasing scrutiny over its operations and credibility in the highly sensitive healthcare segment.